Elevance Health, Inc.
ELVHealthcareNASDAQHealthcare Plans · Last scanned Oct 26, 2026
Scan Results
Daily timeframeElevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The $95.41B market capitalization puts ELV squarely in large-cap range for its industry. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.
Market Cap
$95.41B
Beta
0.71
P/E (TTM)
18.68
P/E (Fwd)
14.56
EPS (TTM)
$23.55
EPS (Fwd)
$30.22
ROE
11.5%
ROA
4.0%
Cash
$37.85B
Total Debt
$30.76B
Free CF
$7.99B
52W Change
28.5%
Annual Financials
Cash vs Debt
Where ELV stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ELV finished 13.62% above its 150-day moving average ($378.67) and 17.22% above its 200-day moving average ($367.04). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ELV overbought or oversold?
At the October 20, 2026 close, ELV's RSI(14) was 78.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $37.85B in cash and $30.76B in debt, ELV maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $7.99B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 11.5% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.0% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $156.59B (2022) to $199.12B (2025), reflecting a 27% increase over the period.
Investors considering Elevance Health, Inc. should weigh the typical risks associated with ELV's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ELV.